Anebulo Pharmaceuticals (OTCMKTS:ANEB – Get Free Report) is projected to announce its results on Wednesday, November 18th. Analysts expect Anebulo Pharmaceuticals to announce earnings of ($0.11) per share for the quarter.
Anebulo Pharmaceuticals Stock Down 9.4%
ANEB opened at $0.26 on Wednesday. Anebulo Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $2.49. The company has a 50 day moving average of $0.30 and a 200 day moving average of $0.45.
Anebulo Pharmaceuticals Company Profile
Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for acute cannabinoid intoxication and related medical emergencies. The company’s work is aimed at addressing the effects of cannabis and synthetic cannabinoids, including situations in which patients require urgent medical care. Anebulo’s lead investigational product, ANEB-001, is an orally administered antagonist of the cannabinoid type 1 (CB1) receptor. The company is developing ANEB-001 to rapidly reverse the effects of cannabinoid intoxication, with potential applications in emergency and acute-care settings.
Read More
- Five stocks we like better than Anebulo Pharmaceuticals
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
